Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Manage your formulary budget
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Radiolabeled technetium chelates for use in renal function determinations|
|Abstract:||The present invention is directed to novel radiopharmaceutical imaging agents incorporating Tc-99m as a radiolabel. In particular, the novel imaging agents disclosed herein have relatively high renal extraction efficiencies, and hence are useful for conducting renal function imaging procedures. The novel Tc-99m compounds of a present invention have the following general formula: ##STR1## wherein X is S or N; and wherein Y is H or wherein Y is ##STR2## and where R.sub.1 is --H, --CH.sub.3, or --CH.sub.2 CH.sub.3 ; R.sub.2 is --H, --CH.sub.2 CO.sub.2 H, --CH.sub.2 CONH.sub.2, --CH.sub.2 CH.sub.2 CO.sub.2 H, --CH.sub.2 CH.sub.2 CONH.sub.2, --CH.sub.3, --CH.sub.2 CH.sub.3, CH.sub.2 C.sub.6 H.sub.5, or --CH.sub.2 OH; and Z is --H, --CO.sub.2 H, --CONH.sub.2, --SO.sub.3 H, --SO.sub.2 NH.sub.2, or --CONHCH.sub.2 CO.sub.2 H; and the Tc is Tc-99m; and water-soluble salts thereof. Of the foregoing, the presently preferred Tc-99m compound of the present invention is Tc-99m-mercaptoacetylglycylglycylglycine (Tc-99m-MAGGG). The present invention is also directed to novel chelating agents that may be reacted with Tc-99m to form the foregoing compounds. Such novel chelating agents have the following general formula. ##STR3## where X and Y have the same definitions as above, and wherein Y' is --H.sub.2 when X is N, or wherein Y' is --H, or a suitable protective group such as --COCH.sub.3, --COC.sub.6 H.sub.5, --CH.sub.2 NHCOCH.sub.3, --COCF.sub.3, or --COCH.sub.2 OH when X is S. The present invention also provides methods for preparing and using the novel Tc-99m compounds.|
|Inventor(s):||Fritzberg; Alan (Edmonds, WA)|
|Assignee:||University of Utah Research Foundation (Salt Lake City, UT)|
1. A prepackaged kit for use in preparing a compound comprising technetium-99m, said compound having the general
formula ##STR18## and water-soluble salts thereof, said prepackaged kit comprising: A container containing a selected quantity of a ligand of the general formula ##STR19## wherein X is S or N; and wherein Y.sup.1 is --H or a group which protects the
sulfur from oxidation where X is S, or wherein Y.sup.1 is --H.sub.2 where X is N; and wherein Y is --H or wherein Y is ##STR20## and where R.sub.1 is --H, --CH.sub.3, or --CH.sub.2 CH.sub.3 ; R.sub.2 is --H, --CH.sub.2 CO.sub.2 H, --CH.sub.2
CONH.sub.2, --CH.sub.2 CH.sub.2 CO.sub.2 H, --CH.sub.2 CH.sub.2 CONH.sub.2, --CH.sub.3, --CH.sub.2 CH.sub.3, or --CH.sub.2 OH; and Z is --H, --CO.sub.2 H, --CONH.sub.2, --SO.sub.3 H, --SO.sub.2 NH.sub.2, or --CONHCH.sub.2 CO.sub.2 H; a suitable amount
of a water soluble stannous salt to induce the reaction of said ligand with a technetium-99m pertechnetate salt; and a suitable amount of an intermediate exchange ligand to complex with said suitable amount of soluble stannous salt, wherein said
container has sufficient volume for accepting a suitable amount of a water soluble technetium-99m pertechnetate salt to provide a desired level of radioactivity.
2. A prepackaged kit as defined in claim 1, wherein X is S.
3. A prepackaged kit as defined in claim 2, wherein, when Y.sup.1 comprises said group which protects the sulfur from oxidation, Y.sup.1 is --COCH.sub.3, --COC.sub.6 H.sub.5, --CH.sub.2 NHCOCH.sub.3, --COCF.sub.3, --COCH.sub.2 CO.sub.2 H, or --COCH.sub.2 OH.
4. A prepackaged kit as defined in claim 2, wherein Y' is --COC.sub.6 H.sub.5, and Y is --CH.sub.2 CO.sub.2 H.
5. A prepackaged kit as defined in claim 2, wherein Y is --CHCH.sub.3 CO.sub.2 H; --CH(CH.sub.2 CONH.sub.2)CO.sub.2 H; or --CH(CH.sub.2 CH.sub.2 CONH.sub.2)COOH.
6. A prepackaged kit as defined in claim 2, wherein the intermediate exchange ligand is acetate, glycine, citrate, malonate, gluconate, tartrate, malate, lactate, hydroxyisobutyrate, pyrophosphate, N-methyl N,N'-bis(2hydroxyethyl)ethylenediamine, or glucoheptonate.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.